FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092937247> ?p ?o ?g. }

• W3092937247 endingPage "2363" @default.
• W3092937247 startingPage "2354" @default.
• W3092937247 abstract "Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. We evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naïve patients with del(17p) disease enrolled in a dedicated, nonrandomized cohort (Arm C) of the phase 3 SEQUOIA trial. A total of 109 patients (median age, 70 years; range, 42 – 86) with centrally confirmed del(17p) were enrolled and treated. After a median of 18.2 months (range, 5.0 – 26.3), seven patients had discontinued study treatment due to progressive disease, four due to an adverse event, and one due to withdrawal of consent. The overall response rate was 94.5% with 3.7% of patients achieving complete response with or without incomplete hematologic recovery. The estimated 18-month progression-free survival rate was 88.6% (95% CI, 79.0 – 94.0) and the estimated 18-month overall survival rate was 95.1% (95% CI, 88.4 – 98.0). Most common all-grade adverse events included contusion (20.2%), upper respiratory tract infection (19.3%), neutropenia/neutrophil count decreased (17.4%), and diarrhea (16.5%). Grade ≥ 3 adverse events were reported in 53 patients (48.6%), most commonly neutropenia (12.9%) and pneumonia (3.7%). An adverse event of atrial fibrillation was reported in three patients (2.8%). Zanubrutinib was active and well tolerated in this large, prospectively enrolled treatment cohort of previously untreated patients with del(17p) chronic lymphocytic leukemia/small lymphocytic lymphoma. This trial was registered at ClinicalTrials.gov as #NCT03336333." @default.
• W3092937247 created "2020-10-22" @default.
• W3092937247 creator A5001388908 @default.
• W3092937247 creator A5001632182 @default.
• W3092937247 creator A5007310385 @default.
• W3092937247 creator A5008054206 @default.
• W3092937247 creator A5012311623 @default.
• W3092937247 creator A5016570475 @default.
• W3092937247 creator A5017472528 @default.
• W3092937247 creator A5019857907 @default.
• W3092937247 creator A5021234553 @default.
• W3092937247 creator A5029774831 @default.
• W3092937247 creator A5030806032 @default.
• W3092937247 creator A5034517642 @default.
• W3092937247 creator A5036608249 @default.
• W3092937247 creator A5038243788 @default.
• W3092937247 creator A5047631289 @default.
• W3092937247 creator A5049924304 @default.
• W3092937247 creator A5050331218 @default.
• W3092937247 creator A5066919823 @default.
• W3092937247 creator A5069054551 @default.
• W3092937247 creator A5077793241 @default.
• W3092937247 creator A5087571749 @default.
• W3092937247 creator A5087770514 @default.
• W3092937247 creator A5087877679 @default.
• W3092937247 creator A5088476247 @default.
• W3092937247 creator A5090258495 @default.
• W3092937247 creator A5090305313 @default.
• W3092937247 date "2020-10-13" @default.
• W3092937247 modified "2023-10-14" @default.
• W3092937247 title "Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion" @default.
• W3092937247 cites W1969716623 @default.
• W3092937247 cites W1969953749 @default.
• W3092937247 cites W2023976667 @default.
• W3092937247 cites W2049103906 @default.
• W3092937247 cites W2066564017 @default.
• W3092937247 cites W2076668534 @default.
• W3092937247 cites W2108206643 @default.
• W3092937247 cites W2129650489 @default.
• W3092937247 cites W2131078883 @default.
• W3092937247 cites W2131900456 @default.
• W3092937247 cites W2134645992 @default.
• W3092937247 cites W2140606816 @default.
• W3092937247 cites W2144617723 @default.
• W3092937247 cites W2158450409 @default.
• W3092937247 cites W2233614027 @default.
• W3092937247 cites W2318933236 @default.
• W3092937247 cites W2323897083 @default.
• W3092937247 cites W2337485820 @default.
• W3092937247 cites W2507865108 @default.
• W3092937247 cites W2519500141 @default.
• W3092937247 cites W2534679415 @default.
• W3092937247 cites W2567446362 @default.
• W3092937247 cites W2623762297 @default.
• W3092937247 cites W2752942423 @default.
• W3092937247 cites W2790385276 @default.
• W3092937247 cites W2790448887 @default.
• W3092937247 cites W2800186514 @default.
• W3092937247 cites W2806698461 @default.
• W3092937247 cites W2902484351 @default.
• W3092937247 cites W2902706178 @default.
• W3092937247 cites W2946200248 @default.
• W3092937247 cites W2946882253 @default.
• W3092937247 cites W2948436219 @default.
• W3092937247 cites W2949959142 @default.
• W3092937247 cites W2964310707 @default.
• W3092937247 cites W2966190920 @default.
• W3092937247 cites W2972482801 @default.
• W3092937247 cites W2987080466 @default.
• W3092937247 cites W2993490427 @default.
• W3092937247 cites W2997469873 @default.
• W3092937247 cites W3012934148 @default.
• W3092937247 cites W3016538158 @default.
• W3092937247 cites W3026096286 @default.
• W3092937247 cites W4376595664 @default.
• W3092937247 doi "https://doi.org/10.3324/haematol.2020.259432" @default.
• W3092937247 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8409041" @default.
• W3092937247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33054121" @default.
• W3092937247 hasPublicationYear "2020" @default.
• W3092937247 type Work @default.
• W3092937247 sameAs 3092937247 @default.
• W3092937247 citedByCount "57" @default.
• W3092937247 countsByYear W30929372472021 @default.
• W3092937247 countsByYear W30929372472022 @default.
• W3092937247 countsByYear W30929372472023 @default.
• W3092937247 crossrefType "journal-article" @default.
• W3092937247 hasAuthorship W3092937247A5001388908 @default.
• W3092937247 hasAuthorship W3092937247A5001632182 @default.
• W3092937247 hasAuthorship W3092937247A5007310385 @default.
• W3092937247 hasAuthorship W3092937247A5008054206 @default.
• W3092937247 hasAuthorship W3092937247A5012311623 @default.
• W3092937247 hasAuthorship W3092937247A5016570475 @default.
• W3092937247 hasAuthorship W3092937247A5017472528 @default.
• W3092937247 hasAuthorship W3092937247A5019857907 @default.
• W3092937247 hasAuthorship W3092937247A5021234553 @default.
• W3092937247 hasAuthorship W3092937247A5029774831 @default.
• W3092937247 hasAuthorship W3092937247A5030806032 @default.
• W3092937247 hasAuthorship W3092937247A5034517642 @default.

• next